A total of 16 patients received MSCs infusions. There were no infusion-related or allergic reactions. The oxygenation index was improved after cell transplantation. The mortality of enrolled patients was 6.25%, whereas the historical mortality rate was 45.4%. The level of cytokines estimated varied in the normal range, the radiological presentations (ground glass opacity) were improved, the lymphocyte count and lymphocyte subsets (CD4+ T cells, CD8+ T cells and NK cells) count showed recovery after cell therapy. The gene discussed is CD8A; the disease is allergic disease.